Morgan Stanley analyst Kallum Titchmarsh lowered the firm’s price target on Grail (GRAL) to $60 from $110 and keeps an Equal Weight rating on the shares. The firm’s lowered target reflects the recent Q4 report as well as the NHS-Galleri topline readout and greater uncertainty in receiving broad reimbursement for Galleri, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRAL: